A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease.

Trial Profile

A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Nov 2016

At a glance

  • Drugs Actoxumab/bezlotoxumab (Primary)
  • Indications Clostridium infections; Diarrhoea
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Jun 2016 Results assessing risk factors for recurrence using data from the placebo arm (n = 99) published in the Clinical Infectious Diseases.
    • 27 Jan 2010 Results have been published in the New England Journal of Medicine.
    • 30 May 2009 Results have been presented at Digestive Disease Week 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top